Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 7, 2020- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 23, 2020Primary and secondary objectives were met with 85% or greater relative reduction achieved in the number of new gadolinium-enhancing T1 and new or enlarging T2 hyperintense lesions
-
Apr 16, 2020- Companies to negotiate a collaboration on the development of a breakthrough COVID-19 self-test solution based on Luminostics’ proprietary technology.
-
Apr 16, 2020- Rolling BLA Submission Initiated Under Breakthrough Therapy Designation
-
Apr 14, 2020Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
-
Apr 9, 2020The award showcases innovative game-changers who are setting the standard for pharmaceutical facilities of the future
-
Apr 3, 2020- Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show adding Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80%
-
Mar 27, 2020* The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development
-
Mar 16, 2020- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis
-
Mar 16, 2020* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
-
Mar 12, 2020- Expect to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
-
Mar 12, 2020-PRV-3279 Inhibited the Function of B Cells, Durably and Without Depletion-
-
Mar 2, 2020* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
-
Feb 19, 2020
-
Feb 18, 2020- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine